The news came from the United States in the afternoon - Washington time - on Wednesday April 29: the Food and Drug Administration, the American government agency that authorizes new drugs or new uses of old drugs, took an official position by announcing that with the goal of "Accelerate the development and availability of potential COVID-19 treatments", the agency requested the pharmaceutical company Gilead Sciences "Making Remdesivir available to patients as quickly as possible, as needed", given the current emergency and despite a promising but still incomplete experimentation.
Recall that this is a broad spectrum antiviral used since 2013 against Ebola but therapeutically effective also against SARS and MERS coronaviruses1. Well, the data just collected during clinical trials suggest that patients with severe COVID-19 who took Remdesivir recover faster than patients treated with simple placebo. The National Institute of Allergies and Infectious Diseases also said on Wednesday, through Dr. Anthony Fauci, explaining that we are experiencing a significant reduction, of just under a third, in healing times. Despite the presence of side effects and with the need to evaluate their use in more in depth patients, "the data show that Remdesivir has a net, significant and positive effect in reducing recovery times"2.
In Italy, the drug was used as an experimental antiviral therapy at the National Institute for Infectious Diseases "Lazzaro Spallanzani" in Rome to treat the Chinese tourist couple found coronavirus positive last January. The Policlinico San Martino in Genoa also had a case of recovery through the experimental administration of Remdesivir.
In conclusion, it is necessary to tell what the Chinese communist government has done, as usual ambiguous and unreliable, to the detriment of the company that holds the patent, Gilead Sciences. The Californian pharmaceutical company, which specializes in antiviral drugs, donated part of its Remdesivir to China for clinical use in the treatment of coronavirus in Wuhan, at the height of the crisis in the People's Republic, between January and February.. She did so even though she had never been granted rights to the drug in communist China, despite a request made in 2016 and which was still outstanding. Well, at the end of the treatment on Wuhan patients, a group of Chinese researchers applied to patent the same drug as Gilead3 in your country. Really people to trust ...